目的 研究益肾排毒方联合非布司他片治疗肾虚血瘀型尿酸性肾病的临床疗效.方法 纳入70例符合肾虚血瘀证型的尿酸性肾病患者,按照随机数字表法将其分为观察组(n=35)和对照组(n=35).对照组给予非布司他片治疗,观察组在对照组基础上给予中药益肾排毒方治疗,2组疗程均为12周.比较2组临床总有效率,治疗前后中医证候评分变化,血尿酸(uric acid,UA)、血清肌酐(ser-um creatinine,Scr)、血尿素氮(blood urea nitrogen,BUN)、胱抑素 C(cystatin C,Cys-C)、24 h 尿蛋白定量(24 h urine protein quantification,24 h Upro)、β2-微球蛋白(β2-microglobulin,β2-MG)等指标变化以及治疗过程中不良反应发生率.结果 治疗后,观察组临床总有效率为91.43％(32/35),对照组为65.71％(23/35),组间比较,差异有统计学意义(P＜0.05).观察组中医证候评分、UA、BUN、Scr、Cys-C以及24 h Upro、β2-MG水平均低于对照组(P均＜0.05),eGFR高于对照组(P＜0.05).治疗过程中,观察组不良反应发生率为5.71％(2/35),对照组为2.86％(1/35),组间比较,差异无统计学意义(P＞0.05).结论 益肾排毒方联合非布司他片治疗肾虚血瘀型尿酸性肾病疗效显著,能够改善患者肾功能,降低24 h Upro、β2-MG水平,缓解临床症状,且具有良好的安全性,值得临床推广.
Clinical Study on the Combination of Yishen Paidu Formula and Febuxostat Tablets in Treating Uric Acid Nephropathy of Kidney Deficiency and Blood Stasis Type
Objective To study the clinical efficacy of Yishen Paidu formula combined with febuxostat tablets in the treatment of uric acid nephropathy of kidney deficiency and blood stasis type.Methods Seventy patients with uric acid nephropathy of kidney deficiency and blood stasis were included and randomly divided into the obser-vation group(n=35)and the control group(n=35)according to the random number table method.The control group was treated with febuxostat tablets,while the observation group was treated with traditional Chinese medi-cine Yishen Paidu formula on the basis of the control group.The treatment course for both groups were 12 weeks.The total clinical effective rate,changes of traditional Chinese medicine syndrome scores,blood uric acid(UA),serum creatinine(Scr),blood urea nitrogen(BUN),cystatin C(Cys-C),24-hour urine protein quantification(24 h Upro)and β2-microglobulin(β2-MG)before and after treatment,as well as the incidence rate of adverse reac-tions in the course of treatment were compared between the two groups.Results After treatment,the total clinical effective rate in the observation group was 91.43％(32/35),while the control group was 65.71％(23/35).There was a statistical difference between the two groups(P＜0.05).The TCM syndrome scores,UA,BUN,Scr,Cys-C as well as 24 h Upro and β2-MG levels of the observation group were lower than those of the control group(all P＜0.05),and eGFR was higher than that of the control group(P＜0.05).During the treatment process,the incidence of adverse reactions in the observation group was 5.71％(2/35),while the control group was 2.86％(1/35).There was no statistical difference between the two groups(P＞0.05).Conclusion The combination of Yishen Paidu for-mula and febuxostat tablets had a significant therapeutic effect on uric acid nephropathy of kidney deficiency and blood stasis type,which could improve renal function,reduce the levels of 24 h Upro and β2-MG,and alleviate the clinical symptoms.Besides,it had good safety and was worthy of clinical promotion.
uric acid nephropathyYishen Paidu formulakidney deficiency and blood stasis typefebuxostat
万方数据
维普
